Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study

Michael D. Subblefield, L. T. Vahdat, C. M. Balmaceda, A. B. Troxel, C. S. Hesdorffer, C. L. Gooch

Research output: Contribution to journalArticle

Abstract

Aims: The appearance of peripheral neuropathy is the dose-limiting toxicity in many chemotherapy protocols, and glutamine has been proposed as a potentially neuroprotective agent in patients receiving paclitaxel. Materials and methods: In this non-randomised study, we assessed neurologic signs and symptoms, and changes in nerve-conduction studies in 46 consecutive patients given high-dose paclitaxel either with (n = 17) or without (n = 29) glutamine. Neurological assessments and electrodiagnostic studies were carried out at baseline and at least 2 weeks (median 32 days) after treatment. Results: Patients who received glutamine developed significantly less weakness (P = 0.02), less loss of vibratory sensation (P = 0.04) and less toe numbness (P = 0.004) than controls. The per cent change in the compound motor action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes after paclitaxel treatment was lower in the glutamine group, but this finding was not statistically significant in these small groups. Conclusions: In this study, serial neurologic assessment of patient symptoms and signs seemed to be a better indicator of a possible glutamine effect than sensory- or motor-nerve-conduction studies. Prospective randomised trials are needed to clarify the effect of glutamine on paclitaxel and other types of chemotherapy-induced neuropathy.

Original languageEnglish (US)
Pages (from-to)271-276
Number of pages6
JournalClinical Oncology
Volume17
Issue number4
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Neuroprotective Agents
Peripheral Nervous System Diseases
Paclitaxel
Glutamine
Neural Conduction
Action Potentials
Drug Therapy
Symptom Assessment
Hypesthesia
Toes
Neurologic Manifestations
Nervous System
Signs and Symptoms
Clinical Studies
Therapeutics

Keywords

  • Breast cancer
  • Chemotherapy
  • Electromyography
  • Glutamine
  • Neuropathy
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Subblefield, M. D., Vahdat, L. T., Balmaceda, C. M., Troxel, A. B., Hesdorffer, C. S., & Gooch, C. L. (2005). Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology, 17(4), 271-276. https://doi.org/10.1016/j.clon.2004.11.014

Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy : A clinical and electrophysiologic study. / Subblefield, Michael D.; Vahdat, L. T.; Balmaceda, C. M.; Troxel, A. B.; Hesdorffer, C. S.; Gooch, C. L.

In: Clinical Oncology, Vol. 17, No. 4, 06.2005, p. 271-276.

Research output: Contribution to journalArticle

Subblefield, Michael D. ; Vahdat, L. T. ; Balmaceda, C. M. ; Troxel, A. B. ; Hesdorffer, C. S. ; Gooch, C. L. / Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy : A clinical and electrophysiologic study. In: Clinical Oncology. 2005 ; Vol. 17, No. 4. pp. 271-276.
@article{26b25755f24d463cbdc1abcc374824c3,
title = "Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study",
abstract = "Aims: The appearance of peripheral neuropathy is the dose-limiting toxicity in many chemotherapy protocols, and glutamine has been proposed as a potentially neuroprotective agent in patients receiving paclitaxel. Materials and methods: In this non-randomised study, we assessed neurologic signs and symptoms, and changes in nerve-conduction studies in 46 consecutive patients given high-dose paclitaxel either with (n = 17) or without (n = 29) glutamine. Neurological assessments and electrodiagnostic studies were carried out at baseline and at least 2 weeks (median 32 days) after treatment. Results: Patients who received glutamine developed significantly less weakness (P = 0.02), less loss of vibratory sensation (P = 0.04) and less toe numbness (P = 0.004) than controls. The per cent change in the compound motor action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes after paclitaxel treatment was lower in the glutamine group, but this finding was not statistically significant in these small groups. Conclusions: In this study, serial neurologic assessment of patient symptoms and signs seemed to be a better indicator of a possible glutamine effect than sensory- or motor-nerve-conduction studies. Prospective randomised trials are needed to clarify the effect of glutamine on paclitaxel and other types of chemotherapy-induced neuropathy.",
keywords = "Breast cancer, Chemotherapy, Electromyography, Glutamine, Neuropathy, Paclitaxel",
author = "Subblefield, {Michael D.} and Vahdat, {L. T.} and Balmaceda, {C. M.} and Troxel, {A. B.} and Hesdorffer, {C. S.} and Gooch, {C. L.}",
year = "2005",
month = "6",
doi = "10.1016/j.clon.2004.11.014",
language = "English (US)",
volume = "17",
pages = "271--276",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy

T2 - A clinical and electrophysiologic study

AU - Subblefield, Michael D.

AU - Vahdat, L. T.

AU - Balmaceda, C. M.

AU - Troxel, A. B.

AU - Hesdorffer, C. S.

AU - Gooch, C. L.

PY - 2005/6

Y1 - 2005/6

N2 - Aims: The appearance of peripheral neuropathy is the dose-limiting toxicity in many chemotherapy protocols, and glutamine has been proposed as a potentially neuroprotective agent in patients receiving paclitaxel. Materials and methods: In this non-randomised study, we assessed neurologic signs and symptoms, and changes in nerve-conduction studies in 46 consecutive patients given high-dose paclitaxel either with (n = 17) or without (n = 29) glutamine. Neurological assessments and electrodiagnostic studies were carried out at baseline and at least 2 weeks (median 32 days) after treatment. Results: Patients who received glutamine developed significantly less weakness (P = 0.02), less loss of vibratory sensation (P = 0.04) and less toe numbness (P = 0.004) than controls. The per cent change in the compound motor action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes after paclitaxel treatment was lower in the glutamine group, but this finding was not statistically significant in these small groups. Conclusions: In this study, serial neurologic assessment of patient symptoms and signs seemed to be a better indicator of a possible glutamine effect than sensory- or motor-nerve-conduction studies. Prospective randomised trials are needed to clarify the effect of glutamine on paclitaxel and other types of chemotherapy-induced neuropathy.

AB - Aims: The appearance of peripheral neuropathy is the dose-limiting toxicity in many chemotherapy protocols, and glutamine has been proposed as a potentially neuroprotective agent in patients receiving paclitaxel. Materials and methods: In this non-randomised study, we assessed neurologic signs and symptoms, and changes in nerve-conduction studies in 46 consecutive patients given high-dose paclitaxel either with (n = 17) or without (n = 29) glutamine. Neurological assessments and electrodiagnostic studies were carried out at baseline and at least 2 weeks (median 32 days) after treatment. Results: Patients who received glutamine developed significantly less weakness (P = 0.02), less loss of vibratory sensation (P = 0.04) and less toe numbness (P = 0.004) than controls. The per cent change in the compound motor action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes after paclitaxel treatment was lower in the glutamine group, but this finding was not statistically significant in these small groups. Conclusions: In this study, serial neurologic assessment of patient symptoms and signs seemed to be a better indicator of a possible glutamine effect than sensory- or motor-nerve-conduction studies. Prospective randomised trials are needed to clarify the effect of glutamine on paclitaxel and other types of chemotherapy-induced neuropathy.

KW - Breast cancer

KW - Chemotherapy

KW - Electromyography

KW - Glutamine

KW - Neuropathy

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=19144370952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19144370952&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2004.11.014

DO - 10.1016/j.clon.2004.11.014

M3 - Article

C2 - 15997923

AN - SCOPUS:19144370952

VL - 17

SP - 271

EP - 276

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 4

ER -